Drug, device companies’ payments to teaching hospitals may spark conflict of interest, study suggests

The research study took a look at 1,281 mentor hospitals, 91 percent of which generated cash from drug- and devicemakers for royalties, continuing education, assessments, speaking costs, space rentals and gifts. One-fifth of these teaching medical facilities got more than 90 percent of the $832 million drug- and devicemakers gave up 2018.

” Financial relationships in between industry and mentor healthcare facilities have the prospective to create disputes of interest as an outcome of the several roles these health centers serve in taking care of clients, training the next generation of healthcare service providers, and performing scientific and translational research study,” the research studys authors wrote in Health Affairs.

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this material? View our policies by clicking here.

In 2018, 529 companies said they made a minimum of one payment to mentor healthcare facilities. About half made medical gadgets and materials, about a quarter made drugs and about a quarter produced a mix of both. More than 58 percent of these companies stated they paid fewer than $100,000 to teaching hospitals, while 60 companies said they made more than $1 million in payments.

Katie Adams –
Wednesday, September 9th, 2020
Print|Email.

More short articles on pharmacy: AbbVie inks $2.9 B offer with Chinese drugmaker to establish brand-new cancer treatmentScience will come 1st in race for coronavirus vaccine, 9 significant drugmakers pledgeFDA establishes vaccine approval standards to counter political impact.

Teaching medical facilities received $832 million in payments from drug- and devicemakers for purposes besides research study in 2018, according to an analysis published Sept. 8 in Health Affairs.